而且健赞自己也声称，她会更积极地寻求(其他)可供选择的买家。
And Genzyme itself announced that it would actively search for an alternative buyer.
所罗门说，他曾在不久前看到过健赞高层的求职简历，但是他还未同那些准备跳槽的高管们联系过。
It is a little early to see CVs coming from the top at Genzyme, Solomon says, but he has had conversations with executives there who are preparing their exits.
健赞的董事会正式地拒绝了赛诺菲·安万特敌意收购其公司的消息新鲜出炉，交易观察家们正满腹猜疑。
Fresh off the news that Genzyme's board officially nixed Sanofi-Aventis' hostile bid for the company, deal-watchers are gathering, full of speculation and possibilities.
对赛诺菲来说，这可能预示着麻烦，赛诺菲正要仰仗健赞的经验以获得蛋白治疗药物并进入罕见病药物市场。
This could portend trouble for sanofi, which is relying on Genzyme's expertise to strengthen its presence in protein-based therapies and the rare-diseases market.
就像大型生物技术公司健赞的首席执行官亨利·特米尔(HenriTermeer)所说，“随着时间的推移，个人化药物的推出，依靠拳头产品的商业模式变得越来越不重要了。”
As Henri Termeer, chief executive of Genzyme, a big biotechnology firm, argues, “the blockbuster model becomes less important over time as specialised therapies take off.”
就像大型生物技术公司健赞的首席执行官亨利·特米尔(HenriTermeer)所说，“随着时间的推移，个人化药物的推出，依靠拳头产品的商业模式变得越来越不重要了。”
As Henri Termeer, chief executive of Genzyme, a big biotechnology firm, argues, “the blockbuster model becomes less important over time as specialised therapies take off.”
应用推荐